Final Prospectus Filed for Resale of 11 Million Shares, Confirming 34% Dilution

summarizeSummary

iBio filed the final prospectus for the resale of over 11 million shares by institutional investors, confirming a significant 34% dilution from a recent private placement.

check_boxKey Events

• Finalizes Resale Registration

  This 424B3 is the final prospectus for the resale of 11,061,738 shares of common stock and pre-funded warrant shares by selling stockholders. This follows the S-3 registration filed on January 30, 2026.

• Significant Dilution Confirmed

  The filing explicitly states that the shares registered for resale represent approximately 34% of the company's currently outstanding common stock, creating a substantial dilutive overhang.

• No Direct Proceeds to Company

  iBio will not receive any proceeds from the sale of these shares by the selling stockholders, except for the nominal exercise price of the pre-funded warrants.

• Origin from Recent Private Placement

  The shares being registered for resale originated from a $26 million private placement completed on January 13, 2026, where shares were sold at $2.35 per common share and $2.349 per pre-funded warrant.

auto_awesomeAnalysis

This 424B3 filing serves as the final prospectus for the resale of 11,061,738 shares of common stock and pre-funded warrant shares by selling stockholders. These shares originated from a $26 million private placement completed on January 13, 2026. The filing explicitly states that these shares represent approximately 34% of the company's outstanding common stock prior to the offering, creating a substantial potential dilutive overhang on the stock. The company will not receive any proceeds from these resales, except for nominal warrant exercise fees. This follows the S-3 registration statement filed on January 30, 2026, which initially registered these shares for resale.